Abstract: The subject invention pertains to methods of treating mental illnesses or conditions characterized by a decreased function of NMDA receptors and/or excessively enhanced glutamate release and activity of non-NMDA receptors (AMPA and/or kainate). Specifically disclosed are methods utilizing BrPhe, or isomers of analogs thereof, for treating or preventing mental illness or conditions such as schizophrenia.

Abstract: Disclosed herein are articles of manufacture that comprise compositions comprising one or more aromatic amino acids, analogs or isomers thereof, and/or combinations thereof. The articles of manufacture are useful for treatment of neurological conditions related to or which can be affected by, modulation of glutamate receptor (GluR) activity.

Abstract: The subject invention pertains to pharmaceutical compositions, articles of manufacture, and methods useful for treatment of neurological conditions related to, or which can be affected by, modulation of glutamate receptor (GluR) activity. The treatment can be either prophylactic in nature or to alleviate symptoms of such neurological conditions. The pharmaceutical compositions of the subject invention include an aromatic amino acid (AAA), an analog or isomer of an AAA, or combinations thereof, and pharmaceutically acceptable carrier or diluent. Methods of the subject invention involve parenterally administering to a patient at least one AAA, an analog or isomer of an AAA, or combination thereof.

Abstract: The subject invention pertains to pharmaceutical compositions, articles of manufacture, and methods useful for treatment of neurological conditions related to, or which can be affected by, modulation of glutamate receptor (GluR) activity. The treatment can be either prophylactic in nature or to alleviate symptoms of such neurological conditions. The pharmaceutical compositions of the subject invention include an aromatic amino acid (AAA), an analog or isomer of an AAA, or combinations thereof, and a pharmaceutically acceptable carrier or diluent. Methods of the subject invention involve parenterally administering to a patient at least one AAA, an analog or isomer of an AAA, or combinations thereof.

Abstract: The subject invention pertains to pharmaceutical compositions, articles of manufacture, and methods useful for treatment of neurological conditions related to, or which can be affected by, modulation of glutamate receptor (GluR) activity. The treatment can be either prophylactic in nature or to alleviate symptoms of such neurological conditions. The pharmaceutical compositions of the subject invention include an aromatic amino acid (AAA), an analog or isomer of an AAA, or combinations thereof, and a pharmaceutically acceptable carrier or diluent. Methods of the subject invention involve parenterally administering to a patient at least one AAA, an analog or isomer of an AAA, or combinations thereof.

Abstract: The subject invention pertains to methods for treatment of neurological conditions related to, or which can be affected by, modulation of glutamate receptor (GluR) activity. The treatment can be either prophylactic in nature or to alleviate symptoms of such neurological conditions as ischemia, stroke, spinal cord injury and traumatic brain injury.

Abstract: The subject invention pertains to pharmaceutical compositions, articles of manufacture, and methods useful for treatment of neurological conditions related to, or which can be affected by, modulation of glutamate receptor (GluR) activity. The treatment can be either prophylactic in nature or to alleviate symptoms of such neurological conditions. The pharmaceutical compositions of the subject invention include an aromatic amino acid (AAA), an analog or isomer of an AAA, or combinatins thereof, and a pharmaceutically acceptable carrier or diluent. Methods of the subject invention involve parenterally administering to a patient at least one AAA, an analog or isomer of an AAA, or combinations thereof.